Previous 10 | Next 10 |
HOUSTON , Aug. 20, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced it ...
HOUSTON , Aug. 11, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced that CEO, John M. Climaco , will be issuing a shareholder web...
HOUSTON , July 22, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today recognizes Gl...
July 15, 2020 Palm Beach, FL – July 15, 2020 – An array of reports have projected that the global brain tumor drugs market will continue to rise for the next several years. One earlier report from January 2019 said that the Global Brain Tumor Therapeutics Market ...
HOUSTON , July 15, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided an update...
July 8, 2020 Palm Beach, FL – July 8, 2020 – The global brain tumor drugs market was valued at about $2.4 billion in 2018 and is expected to grow to $3.41 billion at a CAGR of 9.2% through 2022. The brain tumor drugs market consist of sales of drugs which are used to...
HOUSTON , July 8, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced today it h...
HOUSTON , June 30, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced it ...
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive ...
NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentatio...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NASDAQ Market:
CNS Pharmaceuticals Inc. Website:
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in next month’s 2024 SNO/ASCO CNS Cancer Conference. The event will be held...
HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its ab...
New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant t...